Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/k-bank-co-ltd" target="_blank" data-smartkarma-citation="entities:36073:1" rel="noopener">K Bank (279570 KS)</a> now plans to raise up to US$380m in its upcoming South Korean IPO, after having cancelled its 2024 listing.</li>
<li>K Bank is one of three Internet-only banks in Korea. It provides a full range of commercial banking products and services.</li>
<li>We looked at the refiling updates in our previous note, in this note we provide an updated peer comparison and our thoughts on valuations.</li>
</ul>



K Bank (279570 KS) now plans to raise up to US$380m in its upcoming South Korean IPO, after having cancelled its 2024 listing.
K Bank is one of three Internet-only banks in Korea. It provides a full range of commercial banking products and services.
We looked at the refiling updates in our previous note, in this note we provide an updated peer comparison and our thoughts on valuations.


Aequitas: K Bank IPO - Refiling Updates - Updated Peer Comp and Thoughts on 2026 Valuation

<ul>
<li>In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, having looked at HK and India, we talk about Japan and South Korea pipeline.</li>
<li>This list has been compiled on a best effort basis from tracking the company filings and through various other sources.</li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, having looked at HK and India, we talk about Japan and South Korea pipeline.
This list has been compiled on a best effort basis from tracking the company filings and through various other sources.
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


Aequitas 2026 Asia IPO Pipeline - Japan & South Korea

<ul>
<li>
<a href="https://www.smartkarma.com/entities/k-bank-co-ltd" target="_blank" data-smartkarma-citation="entities:36073:1" rel="noopener">K Bank (279570 KS)</a> now plans to raise up to US$380m in its upcoming South Korean IPO, after having cancelled its 2024 listing.</li>
<li>K Bank is one of three Internet-only banks in Korea. It provides a full range of commercial banking products and services.</li>
<li>In this note, we look at the updates from its recent filings.</li>
</ul>



K Bank (279570 KS) now plans to raise up to US$380m in its upcoming South Korean IPO, after having cancelled its 2024 listing.
K Bank is one of three Internet-only banks in Korea. It provides a full range of commercial banking products and services.
In this note, we look at the updates from its recent filings.


Aequitas: K Bank IPO - Refiling Updates - No Longer Growing Fast, Still with Issues

Equity/Index & Cross Asset Volatility Specialist, Cameron Design

Jay Cameron

Equity/Index & Cross Asset Volatility Specialist

Cameron Design

We specialize in financial products and volatility. Our strategies balance speed, data, and risk control to capture opportunities across global markets. Our research leverages AI and data analytics to continuously refine our algorithms and adapt to evolving market dynamics.

Equity Derivatives

<ul>
<li>Japanese banks are entering a new, structurally sound phase driven by the BoJ's policy pivot, which is fundamentally elevating Net Interest Income and profitability.</li>
<li>Capital efficiency and mandatory corporate governance reforms are set to significantly close the P/B gap against global peers.</li>
<li>TOPIX Bank Index could be poised for continued outperformance over the broader market, making it an essential, high-conviction portfolio exposure as 8303 Shinsei returns to the index.</li>
</ul>


Japanese banks are entering a new, structurally sound phase driven by the BoJ's policy pivot, which is fundamentally elevating Net Interest Income and profitability.
Capital efficiency and mandatory corporate governance reforms are set to significantly close the P/B gap against global peers.
TOPIX Bank Index could be poised for continued outperformance over the broader market, making it an essential, high-conviction portfolio exposure as 8303 Shinsei returns to the index.


Japanese Banks: TPNBNK Structural Sector Buy-Case, Preparing for Shinsei (8303) January Passive Flow

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medical-data-vision-co-ltd" target="_blank" data-smartkarma-citation="entities:8367:1" rel="noopener">Medical Data Vision (3902 JP)</a> was IPOed in 2014. MitCorp sold. Others sold. Fujifilm and Medipal stayed in. The stock ran up. SBI bought from Fujifilm in Nov2020 at ¥2355.</li>
<li>The stock fell, SBI bought more in 2021-2022. Then it fell more in 2023 and SBI bought more, then fell more in 2024 and SBI bought more. </li>
<li>The Nikkei <a href="https://www.nikkei.com/article/DGXZQOUB115D70R10C25A9000000/" target="_blank" rel="noopener">reports</a> today that Nippon Life will announce a TOB on 15 December with a max price of ¥60bn (242% premium), which coincidentally would bring SBI close to breakeven.</li>
</ul>



Medical Data Vision (3902 JP) was IPOed in 2014. MitCorp sold. Others sold. Fujifilm and Medipal stayed in. The stock ran up. SBI bought from Fujifilm in Nov2020 at ¥2355.
The stock fell, SBI bought more in 2021-2022. Then it fell more in 2023 and SBI bought more, then fell more in 2024 and SBI bought more. 
The Nikkei reports today that Nippon Life will announce a TOB on 15 December with a max price of ¥60bn (242% premium), which coincidentally would bring SBI close to breakeven.


[Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn

Japan

SBI Shinsei Bank, Ltd. provides banking services including deposits, loans, and foreign exchange transaction, as well as investment trust service and issuance of long-term bonds.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SBI Shinsei Bank (8303 JP)

Aequitas: K Bank IPO - Refiling Updates - Updated Peer Comp and Thoughts on 2026 Valuation

K Bank (279570 KS) now plans to raise up to US$380m in its upcoming South Korean IPO, after having cancelled its 2024 listing. In this note, we...

Sumeet Singh

Aequitas 2026 Asia IPO Pipeline - Japan & South Korea

In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, having looked at HK and India, we talk about Japan and South Korea...

Sumeet Singh

Aequitas: K Bank IPO - Refiling Updates - No Longer Growing Fast, Still with Issues

K Bank (279570 KS) now plans to raise up to US$380m in its upcoming South Korean IPO, after having cancelled its 2024 listing. In this note, we...

Sumeet Singh

Japanese Banks: TPNBNK Structural Sector Buy-Case, Preparing for Shinsei (8303) January Passive Flow

The IPO of SBI Shinsei Bank (8303) at 1450 per share signals a positive shift for the bank, clearing its legacy JPY370B government bailout debt,...

Jay Cameron

[Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn

The Nikkei reports Nippon Life will launch a TOB to buy out Medical Data Vision at "up to ¥60bn", announcing it tomorrow. That is a whopping 240%...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)